Clinical Trial: Sac-TMT in Vaginal and Vulvar Cancers

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07804966) titled 'Sac-TMT in Vaginal and Vulvar Cancers' on Sept. 01.

Brief Summary: The ARCANA trial (LACOG 1724) is a single-arm, non-randomized, multi-center, parallel, two-cohort Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT, MK-2870) as a second-line or subsequent treatment in patients with advanced or metastatic vaginal and vulvar squamous cell carcinomas. Given the rarity of these cancers and the lack of standard second-line therapies, this study explores sac-TMT, a novel TROP-2-directed antibody-drug conjugate (ADC). TROP-2 is highly expressed in both vulvar and vaginal squamous cell ...